| European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment–update 2019 C Garbe, T Amaral, K Peris, A Hauschild, P Arenberger, L Bastholt, ... European Journal of Cancer 126, 159-177, 2020 | 428 | 2020 |
| Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma–results of a prospective biomarker study A Forschner, F Battke, D Hadaschik, M Schulze, S Weißgraeber, CT Han, ... Journal for Immunotherapy of Cancer 7, 1-15, 2019 | 152 | 2019 |
| The mitogen-activated protein kinase pathway in melanoma part I–activation and primary resistance mechanisms to BRAF inhibition T Amaral, T Sinnberg, F Meier, C Krepler, M Levesque, H Niessner, ... European journal of cancer 73, 85-92, 2017 | 148 | 2017 |
| Castration-resistant prostate cancer: mechanisms, targets, and treatment TMS Amaral, D Macedo, I Fernandes, L Costa Prostate cancer 2012, 2012 | 125 | 2012 |
| European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022 C Garbe, T Amaral, K Peris, A Hauschild, P Arenberger, N Basset-Seguin, ... European Journal of Cancer 170, 236-255, 2022 | 121 | 2022 |
| Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study MV Heppt, T Amaral, KC Kähler, L Heinzerling, JC Hassel, M Meissner, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 117 | 2019 |
| MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition T Amaral, T Sinnberg, F Meier, C Krepler, M Levesque, H Niessner, ... European journal of cancer 73, 93-101, 2017 | 98 | 2017 |
| S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma–short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality‐of … MV Heppt, U Leiter, T Steeb, T Amaral, A Bauer, JC Becker, E Breitbart, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18 (3), 275-294, 2020 | 84 | 2020 |
| S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma (cSCC)–short version, part 2: epidemiology, surgical and systemic treatment of cSCC, follow‐up … U Leiter, MV Heppt, T Steeb, T Amaral, A Bauer, JC Becker, E Breitbart, ... JDDG: Journal der Deutschen Dermatologischen Gesellschaft 18 (4), 400-413, 2020 | 80 | 2020 |
| Merkel cell carcinoma: Epidemiology, pathogenesis, diagnosis and therapy T Amaral, U Leiter, C Garbe Reviews in Endocrine and Metabolic Disorders 18, 517-532, 2017 | 69 | 2017 |
| Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–2036 C Garbe, U Keim, S Gandini, T Amaral, A Katalinic, B Hollezcek, P Martus, ... European Journal of Cancer 152, 18-25, 2021 | 67 | 2021 |
| Time trends in incidence and mortality of cutaneous melanoma in Germany C Garbe, U Keim, TK Eigentler, T Amaral, A Katalinic, B Holleczek, ... Journal of the European Academy of Dermatology and Venereology 33 (7), 1272-1280, 2019 | 66 | 2019 |
| Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients T Amaral, F Kiecker, S Schaefer, H Stege, K Kaehler, P Terheyden, ... Journal for immunotherapy of cancer 8 (1), 2020 | 65 | 2020 |
| MDM2, MDM4 and EGFR amplifications and hyperprogression in metastatic acral and mucosal melanoma A Forschner, FJ Hilke, I Bonzheim, A Gschwind, G Demidov, T Amaral, ... Cancers 12 (3), 540, 2020 | 59 | 2020 |
| The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration S Banerjee, KHJ Lim, K Murali, K Kamposioras, K Punie, C Oing, ... ESMO open 6 (2), 100058, 2021 | 55 | 2021 |
| Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR) A Forschner, F Eichner, T Amaral, U Keim, C Garbe, TK Eigentler Journal of cancer research and clinical oncology 143, 533-540, 2017 | 53 | 2017 |
| Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: a reassessment on the basis of 3 independent stage III melanoma cohorts C Garbe, U Keim, S Suciu, T Amaral, TK Eigentler, A Gesierich, ... Journal of Clinical Oncology 38 (22), 2543-2551, 2020 | 52 | 2020 |
| Targeting tumor-resident mast cells for effective anti-melanoma immune responses S Kaesler, F Wölbing, WE Kempf, Y Skabytska, M Köberle, T Volz, ... JCI insight 4 (19), 2019 | 46 | 2019 |
| Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for … C Garbe, U Keim, T Amaral, C Berking, TK Eigentler, L Flatz, A Gesierich, ... Journal of Clinical Oncology 40 (32), 3741-3749, 2022 | 45 | 2022 |
| European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European … C Garbe, T Amaral, K Peris, A Hauschild, P Arenberger, N Basset-Seguin, ... Treatment-Update, 159-177, 2019 | 45 | 2019 |
Thomas EigentlerDepartment of Dermatology, Venereology and Allergology, Charité BerlinVerified email at charite.de
